In vitro study of Seraspenide on HIV-induced inhibition of granulopoiesis

Eur J Haematol. 1997 Sep;59(3):184-9. doi: 10.1111/j.1600-0609.1997.tb00973.x.

Abstract

Soluble(s) factor(s) produced by HIV-infected cells have been implicated in bone marrow dysfunction observed in AIDS patients. We have shown previously that infected macrophage but not CBMC-derived conditioned medium inhibited the differentiation of purified CD34+ cells, suggesting that accessory cells play a crucial role in granulopoiesis inhibition induced indirectly by HIV. In order to prevent this inhibition we tested the potential protective effect of Seraspenide, a reversible inhibitor of hematopoietic progenitors. We showed that 20 h pretreatment of mononuclear cells with Seraspenide at 10(-10) mol/l prevents CFU-GM inhibition induced by HIV-infected cell-derived conditioned medium.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, CD34 / analysis
  • Cell Differentiation / drug effects
  • Cells, Cultured
  • Culture Media, Conditioned / pharmacology
  • Granulocytes / drug effects*
  • Growth Inhibitors / pharmacology*
  • HIV Infections / immunology*
  • Hematopoiesis / drug effects*
  • Hematopoietic Stem Cells / drug effects*
  • Hematopoietic Stem Cells / virology
  • Humans
  • Leukocytes, Mononuclear / metabolism
  • Leukocytes, Mononuclear / virology*
  • Oligopeptides / pharmacology*
  • T-Lymphocyte Subsets / chemistry

Substances

  • Antigens, CD34
  • Culture Media, Conditioned
  • Growth Inhibitors
  • Oligopeptides
  • goralatide